

# Competitor Analysis: Nonalcoholic Steatohepatitis (NASH) – Novel Drug Candidates

<https://marketpublishers.com/r/CF317F6D98DEN.html>

Date: January 2015

Pages: 25

Price: US\$ 260.00 (Single User License)

ID: CF317F6D98DEN

## Abstracts

### Competitor Analysis: Nonalcoholic Steatohepatitis (NASH) – Novel Drug Candidates

The Competitive Intelligence report about **Nonalcoholic Steatohepatitis (NASH) - Novel Drug Candidates** provides a competitor analysis in the development pipeline of novel therapeutics for treatment of NASH. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Nonalcoholic hepatosteatosis (NASH) is a common, serious chronic liver disease characterized by inflammation and excessive fat accumulation in the liver and may lead to progressive fibrosis, cirrhosis and liver failure. NASH is estimated to affect 10 to 20 percent of people in the developed world. There are currently no approved therapies to treat NASH.

NASH is similar to alcohol-induced steatohepatitis, and is associated with factors that cause an increase in oxidative stress and promote expression of proinflammatory cytokines. NASH is the most common cause of fibrosis and cirrhosis in patients with unexplained increased alanine aminotransferase.

Currently, the diagnosis of hepatic fibrosis is most commonly conducted by a liver biopsy. With magnetic resonance elastography, in use in the United States since 2009 and in Japan since 2012, it has become possible to measure the relative stiffness of liver tissues in a non-invasive manner.

The report provides a compilation of active projects in research and development for treatment of NASH including small molecules, antibodies, peptides and RNAi. Competitor projects are listed in a tabular format providing information on:

Drug Codes

Target / Mechanism of Action

Class of Compound

Company

Product Category

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

### **About Competitor Analysis Series:**

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

## Contents

**CLINICAL STAGE DRUG CANDIDATES FOR TREATMENT OF NASH**

**PRECLINICAL STAGE DRUG CANDIDATES FOR TREATMENT OF NASH**

## I would like to order

Product name: Competitor Analysis: Nonalcoholic Steatohepatitis (NASH) – Novel Drug Candidates

Product link: <https://marketpublishers.com/r/CF317F6D98DEN.html>

Price: US\$ 260.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CF317F6D98DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970